Björn Larsson new CEO of RLS Global
The Board of Directors of RLS Global AB (publ) has today appointed Björn Larsson as new CEO. Björn Larsson, who joins the company from Observe Medical ASA, will assume the role of CEO on 1 October.
Björn Larsson has solid experience from the global medical device and pharmaceutical industry where he has held various positions in companies such as ABIGO Medical AB and AstraZeneca.
“I look forward to leading the company into the next phase and, together with the board and the team, realizing the potential of RLS' unique, patented hypochlorite platform, ChloraSolv. With my experience in the field of wound care, I am convinced that RLS' technology and product portfolio can add significant clinical value and contribute to improved and more efficient care and increased quality of life for the patient”, says Larsson.
In recent years, RLS Global has evolved into a commercial wound care company. The company's strategic focus is to develop ChloraSolv to include new indications and therapeutic areas such as burns, pressure ulcers and animal care, through clinical studies that generate further clinical evidence. In addition, RLS Global focuses on geographic expansion in partnership with ConvaTec and other leading partners.
“It is with pleasure that I welcome Björn Larsson to lead RLS Global into the future. I am convinced that Björn, with his solid experience in medical device, pharmaceuticals and wound care, will lead the commercialization and further development of ChloraSolv in a successful way.
I also want to thank Karin Fischer for her contribution as CEO of RLS Global and wish her the best of luck in her new challenge”, says Steve Krognes, Chairman of the Board.
RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 23-08-2022 09:00 CET.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Steve Krognes, Chairman of the Board
E-mail: customer@rlsglobal.se
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS intends to work with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global